New combo shrinks lung tumors before surgery in targeted drug trial
NCT ID NCT06268210
First seen Feb 12, 2026 · Last updated Apr 30, 2026 · Updated 11 times
Summary
This study tests a drug called lazertinib, given alone or with chemotherapy, before surgery for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). The goal is to see if the drug can shrink tumors enough to improve surgery results. About 160 adults with early to mid-stage lung cancer will take part. The approach aims to control the disease, not cure it, as ongoing monitoring is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.